PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33728029-3 2021 The results showed that resveratrol suppressed TLR4, MMP3, and MMP9 expression in ox-LDL-activated platelets. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 63-67 34402024-9 2021 Analysis of the images on the brain MRI scans revealed that the brain volume of the patients treated with trans-resveratrol was significantly reduced at 52 weeks (P = 0.011) compared with that of patients in the placebo treatment group, Further analysis indicated that the level of matrix metallopeptidase 9 in the CSF of the patients treated with trans-resveratrol at 52 weeks decreased by 46% compared with that of patients in the placebo group (P = 0.033). Resveratrol 106-123 matrix metallopeptidase 9 Homo sapiens 282-307 34402024-9 2021 Analysis of the images on the brain MRI scans revealed that the brain volume of the patients treated with trans-resveratrol was significantly reduced at 52 weeks (P = 0.011) compared with that of patients in the placebo treatment group, Further analysis indicated that the level of matrix metallopeptidase 9 in the CSF of the patients treated with trans-resveratrol at 52 weeks decreased by 46% compared with that of patients in the placebo group (P = 0.033). Resveratrol 348-365 matrix metallopeptidase 9 Homo sapiens 282-307 33723310-0 2021 The effects of resveratrol on the expression of VEGF, TGF-beta, and MMP-9 in endometrial stromal cells of women with endometriosis. Resveratrol 15-26 matrix metallopeptidase 9 Homo sapiens 68-73 33723310-2 2021 The present study has evaluated the effect of resveratrol on the expression of vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-beta) and matrix metalloproteinase-9 (MMP-9) as factors related to endometriosis progression. Resveratrol 46-57 matrix metallopeptidase 9 Homo sapiens 197-202 33723310-5 2021 Also, resveratrol treatment decreased the gene and protein expression of VEGF and MMP-9 in EuESCs, EESCs and CESCs (P < 0.05 to < 0.01 and P < 0.05 to < 0.01 respectively) and gene and protein expression of TGF-beta in EESCs and EuESCs (P < 0.05 to < 0.01). Resveratrol 6-17 matrix metallopeptidase 9 Homo sapiens 82-87 33723310-7 2021 According to the findings, resveratrol may ameliorate endometriosis progression through reducing the expression of VEGF, TGF-beta, and MMP-9 in endometrial stromal cells (ESCs). Resveratrol 27-38 matrix metallopeptidase 9 Homo sapiens 135-140 33728029-6 2021 These findings suggest that the resveratrol-induced inhibition of MMP3 and MMP9 expression is linked to the suppression of TLR4 activation. Resveratrol 32-43 matrix metallopeptidase 9 Homo sapiens 75-79 34008860-6 2021 Interestingly, 50 microM resveratrol treatment could significantly down-regulate the expression of the phosphorylated forms of ERK and p-38, in addition to those of MMP-2 and MMP-9. Resveratrol 25-36 matrix metallopeptidase 9 Homo sapiens 175-180 33728029-5 2021 The combination of resveratrol and CLI-095 synergistically suppressed MMP3 and MMP9 expression in ox-LDL- and LPS-activated platelets. Resveratrol 19-30 matrix metallopeptidase 9 Homo sapiens 79-83 32414118-7 2020 Consequentially, resveratrol reduced PM-induced cyclooxygenase-2/prostaglandin E2 and proinflammatory cytokine expression, including that of matrix metalloproteinase (MMP)-1, MMP-9, and interleukin-8, all of which are known to be central mediators of various inflammatory conditions and aging. Resveratrol 17-28 matrix metallopeptidase 9 Homo sapiens 175-180 32545836-9 2020 Furthermore, resveratrol nanofibers suppressed particulate matter (PM)-induced expression of inflammatory proteins (COX-2 and MMP-9) in HaCaT keratinocytes. Resveratrol 13-24 matrix metallopeptidase 9 Homo sapiens 126-131 30777471-0 2019 The modulating effects of Resveratrol on the expression of MMP-2 and MMP-9 in endometriosis women: a randomized exploratory trial. Resveratrol 26-37 matrix metallopeptidase 9 Homo sapiens 69-74 31009895-0 2019 Pretreatment with resveratrol ameliorate trigeminal neuralgia by suppressing matrix metalloproteinase-9/2 in trigeminal ganglion. Resveratrol 18-29 matrix metallopeptidase 9 Homo sapiens 77-103 31009895-6 2019 However, the activation of MMP-9/2 were suppressed by the pretreatment with resveratrol, which delayed and attenuated CCI-induced mechanical allodynia simultaneously. Resveratrol 76-87 matrix metallopeptidase 9 Homo sapiens 27-32 31009895-9 2019 In conclusion, pretreatment with resveratrol could be an effective approach to alleviate trigeminal neuralgia in early stages via a powerful inhibition on the activation of MMP-9/2 in TG. Resveratrol 33-44 matrix metallopeptidase 9 Homo sapiens 173-178 29921577-2 2018 The natural stilbenoid, resveratrol (RES), exhibits potent antioxidant effects, in a hormetic mode of action, and is known to inhibit MMP-9. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 134-139 30901941-6 2019 An enzyme-linked immunosorbent assay (ELISA) showed that resveratrol can reduce the secretion of matrix metalloproteinase (MMP)-2 and MMP-9. Resveratrol 57-68 matrix metallopeptidase 9 Homo sapiens 134-139 30901941-9 2019 Western blot analysis demonstrated that resveratrol decreased the expression levels of MMP-2, MMP-9, Fibronectin, alpha-SMA, P-PI3K, P-AKT, Smad2, Smad3, P-Smad2, P-Smad3, vimentin, Snail1, and Slug, as well as increased the expression levels of E-cadherin in MDA231 cells. Resveratrol 40-51 matrix metallopeptidase 9 Homo sapiens 94-99 29921577-2 2018 The natural stilbenoid, resveratrol (RES), exhibits potent antioxidant effects, in a hormetic mode of action, and is known to inhibit MMP-9. Resveratrol 37-40 matrix metallopeptidase 9 Homo sapiens 134-139 29340064-5 2017 After treatment with resveratrol, the expression of related Wnt/beta-catenin signaling pathway target genes, such as beta-catenin, c-myc, cyclin D1, MMP-2 and MMP-9, was downregulated and an increased E-cadherin level was observed as well. Resveratrol 21-32 matrix metallopeptidase 9 Homo sapiens 159-164 30002278-7 2018 It is noteworthy that resveratrol strongly suppressed TNF-beta-induced activation of tumor-promoting factors (NF-kappaB, MMP-9, CXCR4) and epithelial-to-mesenchymal-transition-factors (increased vimentin and slug, decreased E-cadherin) in CRC cells. Resveratrol 22-33 matrix metallopeptidase 9 Homo sapiens 121-126 30627191-0 2018 The effect of resveratrol on expression of matrix metalloproteinase 9 and its tissue inhibitors in vascular smooth muscle cells. Resveratrol 14-25 matrix metallopeptidase 9 Homo sapiens 43-69 30627191-4 2018 The aim of this study was to investigate the effect of resveratrol on MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) in vascular smooth muscle cells (VSMCs) after treatment with H2O2. Resveratrol 55-66 matrix metallopeptidase 9 Homo sapiens 70-75 30627191-7 2018 RESULTS: Resveratrol at 120 mumol/l concentration reduced the elevated level of MMP-9 induced by H2O2 in VSMCs as 1.85 +- 0.35 folds (P < 0.050) and 8.70 +- 1.20 folds (P < 0.050) after 24 and 48 hours, respectively. Resveratrol 9-20 matrix metallopeptidase 9 Homo sapiens 80-85 30627191-9 2018 CONCLUSION: Resveratrol as an antioxidant can decrease MMP-9 production, not only by suppressing MMP-9 expression, but also by augmenting TIMP-1 production. Resveratrol 12-23 matrix metallopeptidase 9 Homo sapiens 55-60 30627191-9 2018 CONCLUSION: Resveratrol as an antioxidant can decrease MMP-9 production, not only by suppressing MMP-9 expression, but also by augmenting TIMP-1 production. Resveratrol 12-23 matrix metallopeptidase 9 Homo sapiens 97-102 30627191-10 2018 Altogether, resveratrol as an antioxidant can regulate the MMP-9/TIMP-1 balance, and may be considered as a preservative agent in the treatment and prevention of atherosclerosis. Resveratrol 12-23 matrix metallopeptidase 9 Homo sapiens 59-64 29477771-8 2018 Resveratrol treatment suppressed the CAF-CM-induced expression of Cyclin D1, c-Myc, MMP-2 and MMP-9. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 94-99 28086917-4 2017 RESULTS: Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Resveratrol 61-72 matrix metallopeptidase 9 Homo sapiens 94-98 28000872-4 2017 Resveratrol was shown to significantly inhibit the expression and secretion of matrix metalloproteinase (MMP)-2 and MMP-9 in bladder cancer cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 116-121 28086917-7 2017 CONCLUSIONS: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. Resveratrol 51-62 matrix metallopeptidase 9 Homo sapiens 77-81 27035791-0 2016 Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells. Resveratrol 16-27 matrix metallopeptidase 9 Homo sapiens 69-74 28003970-0 2016 Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK/MMP-9. Resveratrol 11-22 matrix metallopeptidase 9 Homo sapiens 157-162 27601158-7 2016 Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively. Resveratrol 116-127 matrix metallopeptidase 9 Homo sapiens 40-44 26455907-7 2016 This improved outcome was be caused by resveratrol-induced reduction in plasma levels of both matrix metalloproteinase (MMP)-2 and MMP-9, as a positive correlation was observed between reductions in both MMPs and patient NIHSS scores. Resveratrol 39-50 matrix metallopeptidase 9 Homo sapiens 131-136 26310874-6 2015 Further, resveratrol significantly attenuated drug resistance through inhibition of epithelial-mesenchymal transition (EMT) factors (decreased vimentin and slug, increased E-cadherin) and down-regulation of NF-kappaB activation and its translocation to the nucleus and abolished NF-kappaB-regulated gene end-products (MMP-9, caspase-3). Resveratrol 9-20 matrix metallopeptidase 9 Homo sapiens 318-323 27035424-3 2016 The present study aimed to measure the inhibitory effects of resveratrol and genistein on tumor necrosis factor (TNF)-alpha and matrix metalloproteinase (MMP)-9 concentration in patients with COPD. Resveratrol 61-72 matrix metallopeptidase 9 Homo sapiens 128-160 27035424-11 2016 All three factors were significantly reduced in lymphocytes treated with resveratrol and genistein, and the inhibitory effects of resveratrol on NF-kappaB, TNF-alpha and MMP-9 were more potent than the effects of genistein. Resveratrol 130-141 matrix metallopeptidase 9 Homo sapiens 170-175 27035424-12 2016 In conclusion, resveratrol and genistein may inhibit the NF-kappaB, TNF-alpha and MMP-9-associated pathways in patients with COPD. Resveratrol 15-26 matrix metallopeptidase 9 Homo sapiens 82-87 26959057-6 2016 Moreover, resveratrol downregulated nuclear localization of NF-kappaB, NF-kappaB phosphorylation and its acetylation, causing attenuation of NF-kappaB-regulated gene products (MMP-9, CXCR4) involved in tumor-invasion and metastasis. Resveratrol 10-21 matrix metallopeptidase 9 Homo sapiens 141-181 24659233-6 2014 Resveratrol could inhibit the activities of matrix metalloproteinase (MMP) 2 and MMP 9 as shown by zymography. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 81-86 25401496-0 2015 Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 35-61 25401496-6 2015 Zymography, reverse-transcriptase polymerase chain reaction (PCR), and promoter assays confirmed the inhibitory effects of resveratrol on matrix metalloproteinase-9 (MMP-9) expression in oral cancer cells. Resveratrol 123-134 matrix metallopeptidase 9 Homo sapiens 138-164 25401496-6 2015 Zymography, reverse-transcriptase polymerase chain reaction (PCR), and promoter assays confirmed the inhibitory effects of resveratrol on matrix metalloproteinase-9 (MMP-9) expression in oral cancer cells. Resveratrol 123-134 matrix metallopeptidase 9 Homo sapiens 166-171 25401496-8 2015 Zymography and Western blot analyses suggested that resveratrol inhibited TPA-induced MMP-9 gelatinolytic activity and protein expression. Resveratrol 52-63 matrix metallopeptidase 9 Homo sapiens 86-91 25401496-9 2015 In addition, the results indicated that resveratrol inhibited the phosphorylation of c-Jun N-terminal kinase (JNK)1/2 and extracellular-signal-regulated kinase (ERK)1/2 involved in downregulating protein expression and the transcription of MMP-9. Resveratrol 40-51 matrix metallopeptidase 9 Homo sapiens 240-245 25401496-10 2015 CONCLUSION: In summary, resveratrol inhibited MMP-9 expression and oral cancer cell metastasis by downregulating JNK1/2 and ERK1/2 signals pathways and, thus, exerts beneficial effects in chemoprevention. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 46-51 26170816-7 2015 The molecular docking study of resveratrol and MMPs revealed that resveratrol occupied the active site of MMP-2 and MMP-9. Resveratrol 31-42 matrix metallopeptidase 9 Homo sapiens 116-121 26170816-7 2015 The molecular docking study of resveratrol and MMPs revealed that resveratrol occupied the active site of MMP-2 and MMP-9. Resveratrol 66-77 matrix metallopeptidase 9 Homo sapiens 116-121 26170816-10 2015 These findings collectively reveal that resveratrol exhibits neuroprotective effects on cerebral ischemia through inhibiting MMP-2 and MMP-9 activity. Resveratrol 40-51 matrix metallopeptidase 9 Homo sapiens 135-140 24841706-0 2014 Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 23-56 24841706-7 2014 Treatment with SP600125, a JNK inhibitor, attenuated the effects of resveratrol on MMP-2 and MMP-9, and accelerated resveratrol-induced effects on type II collagen, SOX-9 and sulfated proteoglycan production. Resveratrol 68-79 matrix metallopeptidase 9 Homo sapiens 93-98 24841706-3 2014 We found that resveratrol significantly inhibited MMP-2 and MMP-9, and induced the expression of type II collagen and sex-determining region Y-box (SOX)-9 and the production of sulfated proteoglycans in HTB94 chondrosarcoma cells. Resveratrol 14-25 matrix metallopeptidase 9 Homo sapiens 60-65 24841706-6 2014 Treatment with SB203580, a p38 kinase inhibitor, enhanced the suppression of MMP-2 and MMP-9 by resveratrol and inhibited resveratrol-induced stimulation of type II collagen and SOX-9 expression and production of sulfated proteoglycans. Resveratrol 96-107 matrix metallopeptidase 9 Homo sapiens 87-92 24895526-4 2014 Resveratrol-pretreated human monocyte-derived M1 and M2 macrophages were challenged with 7-oxo-cholesterol and analyzed for phenotype and endocytic ability by flow cytometry, for metalloproteinase- (MMP-) 2 and MMP-9 by gelatin zymography, and for cytokine, chemokine, and growth factor secretome by a multiplex immunoassay. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 211-216 24429678-5 2014 Class III HDAC regulation of MMP-9 was assessed using the SIRT1 activators resveratrol and SRT1720 as well as SIRT1 small interfering RNA (siRNA). Resveratrol 75-86 matrix metallopeptidase 9 Homo sapiens 29-34 24429678-9 2014 On the other hand, inhibition of class III HDAC SIRT1 using siRNA significantly augmented IL-1beta-induced MMP-9, and SIRT1 activation using resveratrol and SRT1720 inhibited IL-1beta-induced MMP-9 expression. Resveratrol 141-152 matrix metallopeptidase 9 Homo sapiens 192-197 24895526-6 2014 In the M1 subset, resveratrol prevented the downregulation of CD16 and the upregulation of MMP-2 in response to 7-oxo-cholesterol, whereas in M2 macrophages it prevented the upregulation of CD14, MMP-2, and MMP-9 and the downregulation of endocytosis. Resveratrol 18-29 matrix metallopeptidase 9 Homo sapiens 207-212 24066520-5 2013 Resveratrol reduced the expression of MMP-1 (p = 0.022), MMP-3 (p = 0.021), and MMP-9 (p = 0.047). Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 80-85 23229870-0 2013 Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 20-25 23229870-4 2013 In the present study, we aimed to evaluate the effect of resveratrol on MMPs and cell migration, and to understand the mechanism of action in HT1080 human fibrosarcoma cells. Resveratrol 69-80 matrix metallopeptidase 9 Homo sapiens 84-88 23229870-6 2013 However, resveratrol dramatically increased the activation and expression of MMP-9 in a dose- and time-dependent manner, as determined by gelatin zymography assay and western blot analysis. Resveratrol 9-20 matrix metallopeptidase 9 Homo sapiens 89-94 23229870-9 2013 The inhibition of p38 and Akt kinases with SB203580 and LY294002 further increased resveratrol-induced MMP-9 as well as cell migration in the HT1080 cells. Resveratrol 95-106 matrix metallopeptidase 9 Homo sapiens 115-120 23229870-10 2013 Our results suggest that resveratrol regulates MMP-9 and migratory abilities through the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells. Resveratrol 25-36 matrix metallopeptidase 9 Homo sapiens 47-52 22689577-8 2012 Resveratrol also reversed the IL-1beta- or nicotinamide-induced up-regulation of various gene products that mediate inflammation (cyclooxygenase-2) and matrix degradation (matrix metalloproteinase-9) that are known to be regulated by NF-kappaB. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 172-198 22696189-4 2012 Resveratrol also decreases both the expression and the enzymatic activity of matrix metalloproteinase-9 (MMP-9), and the promoter activity of PMA-stimulated MMP-9 is also inhibited. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 77-103 22696189-4 2012 Resveratrol also decreases both the expression and the enzymatic activity of matrix metalloproteinase-9 (MMP-9), and the promoter activity of PMA-stimulated MMP-9 is also inhibited. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 105-110 22696189-4 2012 Resveratrol also decreases both the expression and the enzymatic activity of matrix metalloproteinase-9 (MMP-9), and the promoter activity of PMA-stimulated MMP-9 is also inhibited. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 157-162 22696189-6 2012 Our results also show that resveratrol suppresses the transcription of MMP-9 by the inhibition of both NF-kappaB and AP-1 transactivation. Resveratrol 27-38 matrix metallopeptidase 9 Homo sapiens 71-76 22696189-7 2012 These results indicate that resveratrol inhibits both NF-kappaB and AP-1 mediated MMP-9 expression, leading to suppression of migration and invasion of human metastatic lung and cervical cancer cells. Resveratrol 28-39 matrix metallopeptidase 9 Homo sapiens 82-87 23992306-4 2013 The results showed that resveratrol not only inhibited cell proliferation, migration, and invasion in a dose-dependent manner, but also mediated the expression of EMT-related genes (E-cadherin, N-cadherin, vimentin, MMP-2, and MMP-9) which are important for cancer cellular motility, invasiveness and metastasis during tumorigenesis. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 227-232 22530672-3 2012 METHODS AND RESULTS: We found that the combination of resveratrol and TMZ significantly resulted in G(2)/M cell cycle arrest by flow cytometry, triggered a robust increase in expression of astrocyte differentiation marker glial fibrillary acid protein (GFAP), downregulated the expression of matrix metalloproteinase-9 (MMP-9) by immunohistochemistry and western blot analysis as well as inhibited cell migration by scratch wound assay. Resveratrol 54-65 matrix metallopeptidase 9 Homo sapiens 292-318 22530672-3 2012 METHODS AND RESULTS: We found that the combination of resveratrol and TMZ significantly resulted in G(2)/M cell cycle arrest by flow cytometry, triggered a robust increase in expression of astrocyte differentiation marker glial fibrillary acid protein (GFAP), downregulated the expression of matrix metalloproteinase-9 (MMP-9) by immunohistochemistry and western blot analysis as well as inhibited cell migration by scratch wound assay. Resveratrol 54-65 matrix metallopeptidase 9 Homo sapiens 320-325 21942447-6 2011 Pretreatment of resveratrol, but not pterostlbene, suppressed EGF-mediated migration and expression of MED28 and matrix metalloproteinase (MMP)-9 in MDA-MB-231 cells. Resveratrol 16-27 matrix metallopeptidase 9 Homo sapiens 113-145 22523472-0 2012 Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 91-96 22523472-7 2012 HBMEC were treated with a combination of resveratrol and phorbol 12-myristate 13-acetate (PMA), a carcinogen known to increase MMP-9 and COX-2 through NF-kappaB. Resveratrol 41-52 matrix metallopeptidase 9 Homo sapiens 127-132 22523472-8 2012 We found that resveratrol efficiently reversed the PMA-induced MMP-9 secretion and COX-2 expression. Resveratrol 14-25 matrix metallopeptidase 9 Homo sapiens 63-68 22523472-11 2012 Our results suggest that resveratrol may prevent BBB disruption during neuroinflammation by inhibiting MMP-9 and COX-2 and act as a pharmacological NF-kappaB signal transduction inhibitor independent of Sirt1. Resveratrol 25-36 matrix metallopeptidase 9 Homo sapiens 103-108 21962734-7 2011 RESULTS: Resveratrol counteracted the CD62L-monocyte subset expansion, CD143 monocyte expression, and circulating levels of MMP-9 activity and TNFalpha associated to AAA induction. Resveratrol 9-20 matrix metallopeptidase 9 Homo sapiens 124-129 21962734-8 2011 Similarly, treatment with Resveratrol significantly attenuated AAA expansion, vessel wall macrophage infiltration and MMP-9, VEGF, and TNFalpha expression, compared with AAA from Et-OH group. Resveratrol 26-37 matrix metallopeptidase 9 Homo sapiens 118-123 20812964-6 2010 The known agonists of Sirt1, resveratrol and metformin, also significantly inhibited MMP-9 expression and appeared to protect collagen from degradation after UVR. Resveratrol 29-40 matrix metallopeptidase 9 Homo sapiens 85-90 21447053-10 2011 In contrast, resveratrol almost completely reduced the release of all cytokines and MMP-9 without significant differences between the cohorts. Resveratrol 13-24 matrix metallopeptidase 9 Homo sapiens 84-89 21238464-5 2011 Western blot analysis and RT-PCR assay were used to determine the effect of resveratrol on the expression level of MMP-9, MAPK and SIRT1 proteins and genes, respectively. Resveratrol 76-87 matrix metallopeptidase 9 Homo sapiens 115-120 21238464-7 2011 Furthermore, it was found that treatment with resveratrol decreased the level of MMP-9 expression via down-regulation of p-ERK, c-fos and p65. Resveratrol 46-57 matrix metallopeptidase 9 Homo sapiens 81-86 21238464-9 2011 SIGNIFICANCE: These results suggest that the activation of SIRT1 in the presence of resveratrol especially inhibits the expression of MMP-9 in HT1080 cells, providing evidence that resveratrol can be a potential candidate for chemoprevention of cancer. Resveratrol 84-95 matrix metallopeptidase 9 Homo sapiens 134-139 21238464-9 2011 SIGNIFICANCE: These results suggest that the activation of SIRT1 in the presence of resveratrol especially inhibits the expression of MMP-9 in HT1080 cells, providing evidence that resveratrol can be a potential candidate for chemoprevention of cancer. Resveratrol 181-192 matrix metallopeptidase 9 Homo sapiens 134-139 19908231-7 2010 Resveratrol inhibited the proliferation of 4 different human PaCa cell lines, synergized the apoptotic effects of gemcitabine, inhibited the constitutive activation of NF-kappaB and expression of bcl-2, bcl-xL, COX-2, cyclin D1 MMP-9 and VEGF. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 228-233 19908231-10 2010 As compared to vehicle control, resveratrol also suppressed the NF-kappaB activation and expression of cyclin D1, COX-2, ICAM-1, MMP-9 and survivin. Resveratrol 32-43 matrix metallopeptidase 9 Homo sapiens 129-134 20461740-7 2010 Resveratrol significantly inhibited HO-1-mediated MMP-9 (35% inhibition) and MMP-2 (28% inhibition) expression in lung cancer cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 50-55 20461740-10 2010 Our results suggest that resveratrol inhibited HO-1 and subsequently MMP-9 and MMP-2 expression in lung cancer cells. Resveratrol 25-36 matrix metallopeptidase 9 Homo sapiens 69-74 19371443-7 2009 The results showed that both MMP-9 mRNA expression and enzymatic activity were gradually increased with the concentration increase of TCDD in media and these changes could be reversed by RSV treatment in a dose-dependent manner. Resveratrol 187-190 matrix metallopeptidase 9 Homo sapiens 29-34 20131808-7 2010 Upon incubation of PMA-treated HepG2 cells with resveratrol (0-50 microM) or MR-3 (0-50 microM), the MMP-9 activity decreased but TIMP-1 protein increased in a dose-dependent manner. Resveratrol 48-59 matrix metallopeptidase 9 Homo sapiens 101-106 20131808-8 2010 With resveratrol (0-50 microM) or MR-3 (0-1 microM) treatment on PMA-untreated Hep3B cells, both of the MMP-9 and MMP-2 activities decreased but TIMP-2 protein increased in a dose-dependent manner. Resveratrol 5-16 matrix metallopeptidase 9 Homo sapiens 104-109 20131808-9 2010 These results suggest that resveratrol and its related methoxy analogue MR-3 might exert anti-invasive activity against hepatoma cells through regulation of MMP-2, MMP-9, TIMP-1, and TIMP-2. Resveratrol 27-38 matrix metallopeptidase 9 Homo sapiens 164-169 20131808-10 2010 Further analysis with semiquantitative RT-PCR showed that the regulation of MMP-9 and TIMP-2 expressions by resveratrol and MR-3 in hepatoma cells may be on the transcriptional level but on the translational or post-translational level for TIMP-1. Resveratrol 108-119 matrix metallopeptidase 9 Homo sapiens 76-81 19889203-8 2009 RESULTS: Treatment with curcumin and resveratrol suppressed NF-kappaB-regulated gene products involved in inflammation (cyclooxygenase-2, matrix metalloproteinase (MMP)-3, MMP-9, vascular endothelial growth factor), inhibited apoptosis (Bcl-2, Bcl-xL, and TNF-alpha receptor-associated factor 1) and prevented activation of caspase-3. Resveratrol 37-48 matrix metallopeptidase 9 Homo sapiens 172-177 19135132-0 2009 Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 21-26 18334147-0 2008 [Effects of resveratrol on matrix metalloproteinase-9 expression in hepatoma cells]. Resveratrol 12-23 matrix metallopeptidase 9 Homo sapiens 27-53 18823944-9 2008 Glucose-induced MMP9 expression was also inhibited by SIRT1 in response to Resveratrol. Resveratrol 75-86 matrix metallopeptidase 9 Homo sapiens 16-20 18674879-4 2008 These results showed that, resveratrol can restrict the migration, adhesion, invasion and MMP-9 and MMP-2 secretion in Lovo cells cultured under normoxia and hypoxia. Resveratrol 27-38 matrix metallopeptidase 9 Homo sapiens 90-95 18674879-5 2008 Hypoxia and iron chelator 2,2"-dipyridyl treatment can stimulate the invasion and migration enhancement of Lovo cells, while resveratrol exhibited substantial resistance on the metastasis potential stimulation by inhibiting the mRNA expression of VEGF and MMP-9 in colon carcinoma cells under normoxia and hypoxia, reducing HIF-1 alpha protein expression under hypoxia. Resveratrol 125-136 matrix metallopeptidase 9 Homo sapiens 256-261 17651959-5 2008 However, the inhibitory effect of resveratrol on HER-2-mediated expression of MMP-9 has not been demonstrated yet. Resveratrol 34-45 matrix metallopeptidase 9 Homo sapiens 78-83 17651959-12 2008 Resveratrol significantly inhibited HRG-beta1-mediated MMP-9 expression in human breast cancer cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 55-60 17651959-16 2008 Taken together, our results suggest that resveratrol inhibited MMP-9 expression in human breast cancer cells. Resveratrol 41-52 matrix metallopeptidase 9 Homo sapiens 63-68 17651959-17 2008 The inhibitory effects of resveratrol on MMP-9 expression and invasion of breast cancer cells are, in part, associated with the down-regulation of the MAPK/ERK signaling pathway. Resveratrol 26-37 matrix metallopeptidase 9 Homo sapiens 41-46 18606398-6 2008 In this study we provide experimental evidence that resveratrol inhibits the expression of VEGF, MMP-3, MMP-9 and COX-2 in human articular chondrocytes stimulated with the pro-inflammatory cytokine IL-1beta. Resveratrol 52-63 matrix metallopeptidase 9 Homo sapiens 104-109 17988825-0 2008 Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 58-84 17988825-6 2008 Resveratrol significantly inhibited TNF-alpha-mediated MMP-9 expression in HepG2 cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 55-60 17988825-9 2008 Our results showed that resveratrol inhibited TNF-alpha-mediated MMP-9 expression and invasion of human hepatocellular carcinoma cells. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 65-70 18334147-7 2008 Moreover, both MMP-9 mRNA expression and MMP-9 protein production were markedly reduced after resveratrol treatment. Resveratrol 94-105 matrix metallopeptidase 9 Homo sapiens 15-20 18334147-7 2008 Moreover, both MMP-9 mRNA expression and MMP-9 protein production were markedly reduced after resveratrol treatment. Resveratrol 94-105 matrix metallopeptidase 9 Homo sapiens 41-46 18334147-8 2008 CONCLUSION: Resveratrol can inhibit the proliferation of SMMC-7721 cells and down-regulate MMP-9 expression. Resveratrol 12-23 matrix metallopeptidase 9 Homo sapiens 91-96 17935668-13 2007 Furthermore, decreased levels of VEGF, bFGF, MMP-2 and MMP-9 mRNA from cells treated with various concentrations of resveratrol confirmed its antiangiogenic action at the level of gene expression. Resveratrol 116-127 matrix metallopeptidase 9 Homo sapiens 55-60 17935668-11 2007 Treatment of RPMI 8226 cells with resveratrol caused a decrease in MMP-2 and MMP-9 activity. Resveratrol 34-45 matrix metallopeptidase 9 Homo sapiens 77-82 17935668-14 2007 CONCLUSIONS: Resveratrol inhibits multiple myeloma angiogenesis by regulating expression and secretion of VEGF, bFGF, MMP-2 and MMP-9. Resveratrol 13-24 matrix metallopeptidase 9 Homo sapiens 128-133 17055343-3 2007 Both resveratrol and a PPARgamma agonist, pioglitazone, significantly inhibited EMMPRIN expression and MMP-9 activity in a concentration-dependent manner. Resveratrol 5-16 matrix metallopeptidase 9 Homo sapiens 103-108 17055343-5 2007 Thus, data suggest that resveratrol may down-regulate EMMPRIN and MMP-9 through PPARgamma activation. Resveratrol 24-35 matrix metallopeptidase 9 Homo sapiens 66-71 20368952-8 2007 In addition, 25 microM resveratrol mitigated the MMP-9 activity of THP-1 cells, followed by a marked inhibition of transendothelial migration. Resveratrol 23-34 matrix metallopeptidase 9 Homo sapiens 49-54 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 269-295 17007354-9 2006 Resveratrol significantly activated PPARgamma and GW9662 greatly decreased the effect of resveratrol on EMMPRIN and MMP-9. Resveratrol 89-100 matrix metallopeptidase 9 Homo sapiens 116-121 17007354-11 2006 Resveratrol can significantly inhibit EMMPRIN expression via activating PPARgamma, which may be the underlying mechanism of its inhibitory effect on MMPs production by monocytes/macrophages. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 149-153 16490592-8 2006 Resveratrol also down-regulated the expression of NF-kappaB-regulated gene products by Western blot analysis, gelatin zymography, and enzyme-linked immunosorbent assay, including interleukin-6, Bcl-2, Bcl-xL, XIAP, c-IAP, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9), which modulates an array of signals controlling cellular survival and proliferation and tumor promotion. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 297-302 14515793-7 2003 Gelatin zymography results showed that MMP-9 expression in U937 cells increased significantly after exposed to PMA at 1 x 10(-8) mol.L-1 (P < 0.001); MMP-9 expression induced with phorbol myristate acetate(PMA) was inhibited by dexamethasone at 1 x 10(-9), 1 x 10(-7) and 1 x 10(-5) mol.L-1, indomethacin at 1 x 10(-6) and 1 x 10(-5) mol.L-1 and resveratrol at 1 x 10(-6) and 1 x 10(-5) mol.L-1. Resveratrol 349-360 matrix metallopeptidase 9 Homo sapiens 39-44 14515793-7 2003 Gelatin zymography results showed that MMP-9 expression in U937 cells increased significantly after exposed to PMA at 1 x 10(-8) mol.L-1 (P < 0.001); MMP-9 expression induced with phorbol myristate acetate(PMA) was inhibited by dexamethasone at 1 x 10(-9), 1 x 10(-7) and 1 x 10(-5) mol.L-1, indomethacin at 1 x 10(-6) and 1 x 10(-5) mol.L-1 and resveratrol at 1 x 10(-6) and 1 x 10(-5) mol.L-1. Resveratrol 349-360 matrix metallopeptidase 9 Homo sapiens 153-158 16317118-10 2005 Furthermore, zymographic and immunoblot analyses showed that RV dose dependently suppressed the TNF-alpha-induced expression of MMP-9. Resveratrol 61-63 matrix metallopeptidase 9 Homo sapiens 128-133 14661062-3 2004 We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. Resveratrol 14-25 matrix metallopeptidase 9 Homo sapiens 111-116 14661062-4 2004 These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. Resveratrol 17-28 matrix metallopeptidase 9 Homo sapiens 86-91 14661062-5 2004 PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Resveratrol 88-99 matrix metallopeptidase 9 Homo sapiens 39-44 14661062-6 2004 Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-kappaB response element. Resveratrol 149-160 matrix metallopeptidase 9 Homo sapiens 33-38 14661062-8 2004 Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-delta may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors. Resveratrol 61-72 matrix metallopeptidase 9 Homo sapiens 32-37 14627504-0 2003 Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 21-47 14627504-1 2003 AIM: To examine the inhibitory effect of resveratrol on matrix metalloroteinase-9 (MMP-9) and explore its mechanism. Resveratrol 41-52 matrix metallopeptidase 9 Homo sapiens 83-88 14627504-5 2003 Resveratrol at 1 and 10 micromol/L showed significant inhibition on MMP-9 activity (P<0.05 and P<0.01, respectively). Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 68-73 14627504-7 2003 Resveratrol at 1 and 10 micromol/L showed inhibitory effects on MMP-9 protein production and MMP-9 mRNA expression (P<0.05). Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 64-69 14627504-7 2003 Resveratrol at 1 and 10 micromol/L showed inhibitory effects on MMP-9 protein production and MMP-9 mRNA expression (P<0.05). Resveratrol 0-11 matrix metallopeptidase 9 Homo sapiens 93-98 14627504-9 2003 CONCLUSION: The inhibitory effect of resveratrol on MMP-9 activity may be partly through suppression of activation of nuclear transcription factor AP-1, and inhibition of MMP-9 mRNA expression and MMP-9 protein production. Resveratrol 37-48 matrix metallopeptidase 9 Homo sapiens 52-57